Species |
Human |
Protein Construction |
SLAMF7 (Ser23-Met226) Accession # Q9NQ25 |
Poly-His |
Avi |
N-term |
|
C-term |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
≤ 1 EU/μg of protein by LAL method |
Biological Activity |
Immobilized SLAMF7, His & Avi Tag at 1.0 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA. |
Expression System |
Expi293 |
Apparent Molecular Weight |
40~50 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. Normally 5 % trehalose is added as protectant before lyophilization. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in distilled water up to 100 μg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Avoid repeated freeze-thaw cycles. |
![CS1/CRACC/SLAMF7, His & Avi, Human CS1/CRACC/SLAMF7, His & Avi, Human](/product/documents/down?doc_name=Z03649_ELISA.JPG&file=scm_files/productFile_notes/2021/06/18/68fd0c31-4b29-4370-b7b7-0e9400ee4725.JPG)
Immobilized SLAMF7, His & Avi tag at 1 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA.
![CS1/CRACC/SLAMF7, His & Avi, Human CS1/CRACC/SLAMF7, His & Avi, Human](/product/documents/down?doc_name=Z03649_SDS-PAGE.JPG&file=scm_files/productFile_notes/2021/06/18/2837c2cc-3eb0-4835-927a-5a7603444e0f.JPG)
Recombinant Human CRACC/SLAMF7 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.
![CS1/CRACC/SLAMF7, His & Avi, Human CS1/CRACC/SLAMF7, His & Avi, Human](/product/documents/down?doc_name=Z03649_SEC-HPLC.JPG&file=scm_files/productFile_notes/2021/06/18/ddaf4b3c-ee19-4a7e-accf-2da74bd11658.JPG)
The purity of Recombinant Human CRACC/SLAMF7 Protein is greater than 95% as determined by SEC-HPLC.
![CS1/CRACC/SLAMF7, His & Avi, Human CS1/CRACC/SLAMF7, His & Avi, Human](/product/documents/down?doc_name=Z03649_ELISA.JPG&file=scm_files/productFile_notes/2021/06/18/3bca4c88-56cb-4fc3-a2d9-da9d2a0c7287.JPG)
Immobilized SLAMF7, His & Avi tag at 1 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA.
![CS1/CRACC/SLAMF7, His & Avi, Human CS1/CRACC/SLAMF7, His & Avi, Human](/product/documents/down?doc_name=Z03649_SDS-PAGE.JPG&file=scm_files/productFile_notes/2021/06/18/5227fa28-e93f-4c03-962c-2791e8dfb21c.JPG)
Recombinant Human CRACC/SLAMF7 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.
![CS1/CRACC/SLAMF7, His & Avi, Human CS1/CRACC/SLAMF7, His & Avi, Human](/product/documents/down?doc_name=Z03649_SEC-HPLC.JPG&file=scm_files/productFile_notes/2021/06/18/522db658-a314-441a-88d0-bb925ad6d10b.JPG)
The purity of Recombinant Human CRACC/SLAMF7 Protein is greater than 95% as determined by SEC-HPLC.
Target Background |
CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family, a self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune responses. |
Synonyms |
CD319 antigen; CD319; 19A; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CRACC; CRACCCD2-like receptor-activating cytotoxic cells; CS119A24 protein; Membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; Novel Ly9; Protein 19A; SLAM family member 7; SLAMF7; CS1 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.